JP2024515830A5 - - Google Patents

Info

Publication number
JP2024515830A5
JP2024515830A5 JP2023566515A JP2023566515A JP2024515830A5 JP 2024515830 A5 JP2024515830 A5 JP 2024515830A5 JP 2023566515 A JP2023566515 A JP 2023566515A JP 2023566515 A JP2023566515 A JP 2023566515A JP 2024515830 A5 JP2024515830 A5 JP 2024515830A5
Authority
JP
Japan
Prior art keywords
compound
degrees
dose
subject
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566515A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515830A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026908 external-priority patent/WO2022232494A1/en
Publication of JP2024515830A publication Critical patent/JP2024515830A/ja
Publication of JP2024515830A5 publication Critical patent/JP2024515830A5/ja
Pending legal-status Critical Current

Links

JP2023566515A 2021-04-29 2022-04-29 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド Pending JP2024515830A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163181807P 2021-04-29 2021-04-29
US63/181,807 2021-04-29
PCT/US2022/026908 WO2022232494A1 (en) 2021-04-29 2022-04-29 Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female

Publications (2)

Publication Number Publication Date
JP2024515830A JP2024515830A (ja) 2024-04-10
JP2024515830A5 true JP2024515830A5 (cg-RX-API-DMAC7.html) 2025-05-09

Family

ID=81748326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566515A Pending JP2024515830A (ja) 2021-04-29 2022-04-29 母乳を出している女性における大うつ病性障害および産後うつ病の処置における使用のための神経活性ステロイド

Country Status (9)

Country Link
US (1) US20240216396A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329769A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515830A (cg-RX-API-DMAC7.html)
CN (1) CN117580580A (cg-RX-API-DMAC7.html)
AU (1) AU2022267304A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217866A1 (cg-RX-API-DMAC7.html)
IL (1) IL307980A (cg-RX-API-DMAC7.html)
MX (1) MX2023012728A (cg-RX-API-DMAC7.html)
WO (1) WO2022232494A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62761B1 (sr) 2012-08-21 2022-01-31 Sage Therapeutics Inc Alopregnanolon za lečenje refraktornog epileptičkog statusa
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
US20200291059A1 (en) 2017-12-08 2020-09-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
EP3678670A1 (en) * 2017-09-07 2020-07-15 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2022514510A (ja) * 2018-12-14 2022-02-14 プラクシス プレシジョン メディスンズ,インコーポレイテッド うつ病の治療方法
CA3187178A1 (en) 2020-07-20 2022-01-27 Sage Therapeutics, Inc. Formulations of 19-nor c3,3- disubstituted c21-n-pyrazolyl steroid and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2024515829A5 (cg-RX-API-DMAC7.html)
JP2024540183A5 (cg-RX-API-DMAC7.html)
JP2021525729A5 (cg-RX-API-DMAC7.html)
US11369654B2 (en) Application method of Dendrobium candidum in preparing medicine for treating hypertension
JP2007533687A5 (cg-RX-API-DMAC7.html)
WO2020223431A1 (en) Combination therapies comprising apremilast and tyk2 inhibitors
CN113304166A (zh) 核苷类化合物在治疗冠状病毒感染性疾病中的用途
JP2011190199A (ja) 関節リウマチ薬
JP2020504129A (ja) 非アルコール性脂肪性肝炎(nash)および肝線維症のための併用療法
JPWO2023054732A5 (cg-RX-API-DMAC7.html)
JP2016507500A5 (cg-RX-API-DMAC7.html)
JP2023553253A5 (cg-RX-API-DMAC7.html)
WO2022166599A1 (zh) Pqq 及其衍生物的新应用
JP2004525940A (ja) 火照りの処置のためのデュロキセチン
JP2023509698A5 (cg-RX-API-DMAC7.html)
JP2019507786A5 (cg-RX-API-DMAC7.html)
JP2024525897A5 (cg-RX-API-DMAC7.html)
JP5341037B2 (ja) 双極性障害を処置するための医薬を得るためのアゴメラチンの使用
JP2022058873A5 (cg-RX-API-DMAC7.html)
JP2006505548A (ja) Pparリガンドと抗酸化剤の会合および肥満の治療のためのその使用
JP4652689B2 (ja) 骨再生を促進するカルモジュリンの使用
WO2011070125A1 (en) Mucoadhesive buccal tablets for the treatment of orofacial herpes
Hoagland et al. Antihistaminic drugs for colds: evaluation based on a controlled study
JP2015520759A5 (cg-RX-API-DMAC7.html)
JP2021530568A5 (cg-RX-API-DMAC7.html)